RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00729638
Recruitment Status : Completed
First Posted : August 7, 2008
Last Update Posted : August 11, 2014
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Medical College of Wisconsin
Information provided by (Responsible Party):
Noopur Raje, Massachusetts General Hospital

Brief Summary:
The purpose of this research study is to determine the highest dose of lenalidomide and RAD001 that can be given without causing too many serious side effects. Another goal of this research study is to look at how the participants cancer may respond to the study treatment. Additionally, we wish to learn more about how the body breaks down and gets rid of the study drugs. We will also try to find substances in the blood (biomarkers) that may help predict how myeloma will respond to study treatment.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: RAD001 Drug: lenalidomide Phase 1

Detailed Description:
  • Researchers are looking for the highest doses of RAD001 and lenalidomide used in combination that can be given safely so small groups of people will be enrolled in steps in this trial. The first group will be given a certain dose of RAD001 and a certain dose of lenalidomide. If they have few or manageable side effects, the next small group of people will be enrolled with a higher dose of RAD001 and/or a higher dose of lenalidomide. This will continue until the highest dose of the drugs used is determined.
  • Study treatment will be given in 28 day cycles. Both RAD001 and lenalidomide are pills that are taken orally. Both drugs will be started on the same day. RAD001 will be taken either every other day or every day for the first 3 weeks (days 1-21) of each 28-day cycle. Lenalidomide will be taken daily for the first 3 weeks (days 1-21) of each cycle.
  • Participants will come to the clinic weekly during the first cycle to monitor side effects. The following will be performed at these clinic visits: physical examination, medical history update, questionnaires, and blood work.
  • On cycles 2-8, participants will come to the clinic on Day 1 of each cycle. The following will be performed at this clinic visit: physical examination, medical history update, questionnaire, and blood word.
  • At the end of cycle 8, a skeletal survey, bone marrow aspiration and biopsy will be performed to check response to study treatment.
  • Participants may continue to receive RAD001 and lenalidomide beyond 8 cycles if their cancer does not get worse and they do not have unacceptable side effects.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Phase I Study of the Safety of and Efficacy of RAD001 in Combination With Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Study Start Date : June 2008
Actual Primary Completion Date : November 2009
Actual Study Completion Date : November 2009

Arm Intervention/treatment
Experimental: Single arm
Single arm phase I study
Drug: RAD001
Dose levels will change: Taken orally either every other day for the first three weeks of each cycle or taken every day for the first three weeks of each cycle.
Drug: lenalidomide
Dose level will vary: taken orally 30-60 minutes after taking RAD001 every day for the first three weeks of each cycle.

Primary Outcome Measures :
  1. To evaluate the safety of RAD001 when given in combination with lenalidomide and to identify the maximum tolerated dose (MTD) as well as a recommended Phase 2 dose for the combination in this patient population. [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. To evaluate the response to the combination of RAD001 and lenalidomide in subjects with multiple myeloma. [ Time Frame: 2 years ]
  2. To determine the pharmacokinetics of RAD001 and lenalidomide. [ Time Frame: 2 years ]
  3. To identify possible surrogate markers to better define mechanisms of action for the combination of the two drugs. [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject was previously diagnosed with multiple myeloma bases on standard criteria listed in protocol
  • Patients must have relapsed or relapsed/refractory disease
  • 18 years of age or older
  • All necessary baseline studies for determining eligibility must be obtained within 21 days prior to enrollment
  • ECOG Performance Status of 0 to 2
  • Able to take aspirin (81 or 325mg) daily as prophylactic anticoagulation
  • Prior thalidomide/lenalidomide therapy is allowed
  • Able to take bactrim
  • Female of childbearing potential must have a negative serum or urine pregnancy test

Exclusion Criteria:

  • Renal insufficiency
  • Concommitant therapy medications that include corticosteroids or other chemotherapy that is or may be active against myeloma or therapy with chemotherapy within 2 weeks prior to day 1. Nitrosoureas must be discontinued 6 weeks prior to day 1. Concurrent radiation therapy is not permitted.
  • Subjects with evidence of mucosal or internal bleeding and/or platelet refractory
  • Subjects with poorly controlled diabetes mellitus
  • Subjects with an ANC < 10-00 cells/mm3
  • Subjects with a hemoglobin < 8.0 g/Dl
  • AST (SGOT and ALT (SGPT) greater or equal to 2x ULN
  • Prior therapy with RAD001
  • Known hypersensitivity to thalidomide or lenalidomide
  • Any condition, including laboratory abnormalities, that in the opinion of the Investigator, places the subject at unacceptable risk if he/she were to participate in the study
  • Clinically relevant active infection or serious co-morbid medical conditions such as recent thromboembolic disease are ineligible if occurred less than 2 weeks prior to enrollment or clinically unstable
  • Chronic obstructive or chronic restrictive pulmonary disease, difficult to control diabetes, upper gastrointestinal ulceration, and cirrhosis
  • Prior malignancy (within the last 3 years) except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, in situ prostate cancer or other cancer for which the subject has been disease-free for at least 3 years
  • Pregnant or breast-feeding females
  • Prior treatment with any investigational drug within preceding 4 weeks
  • Major surgery, and or radiation with 2 weeks of study initiation
  • Uncontrolled leptomeningeal disease
  • Prior treatment with other mTOR inhibitors
  • The use of G-CSF is not permitted to render the patient eligible fot the study
  • POEMS syndrome
  • Known HIV infection
  • Known active Hepatitis B or C infection
  • Myocardial infarction within 6 months prior to enrollment or has NYHA Class III or IV heart failure, uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
  • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001
  • Patients with active, bleeding diathesis or on oral anti-vitamin K medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00729638

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
United States, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226`
Sponsors and Collaborators
Massachusetts General Hospital
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Medical College of Wisconsin
Principal Investigator: Noopur Raje, MD Massachusetts General Hospital

Publications of Results:
Responsible Party: Noopur Raje, Director, Center for Multiple Myeloma, Massachusetts General Hospital Identifier: NCT00729638     History of Changes
Other Study ID Numbers: 07-288
First Posted: August 7, 2008    Key Record Dates
Last Update Posted: August 11, 2014
Last Verified: August 2014

Keywords provided by Noopur Raje, Massachusetts General Hospital:
relapsed multiple myeloma
refractory multiple myeloma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents
Immunosuppressive Agents
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic